T
This company develops a therapeutic platform designed to improve outcomes for patients with solid tumors, specifically targeting liver and pancreatic cancers. Their approach integrates novel drug delivery technology with immunotherapies to overcome intratumoral pressure and the immunosuppressive tumor microenvironment. The platform aims to enhance the efficacy of standard-of-care therapies and investigational immunotherapies in these difficult-to-treat cancers.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company develops a therapeutic platform designed to improve outcomes for patients with solid tumors, specifically targeting liver and pancreatic cancers. Their approach integrates novel drug delivery technology with immunotherapies to overcome intratumoral pressure and the immunosuppressive tumor microenvironment. The platform aims to enhance the efficacy of standard-of-care therapies and investigational immunotherapies in these difficult-to-treat cancers.